Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes

Djordje S Popovic; Dimitrios Patoulias; Luigi Gnudi; Christos S Mantzoros

doi:10.1016/j.metabol.2023.155763

Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes

Metabolism. 2024 Feb:151:155763. doi: 10.1016/j.metabol.2023.155763. Epub 2023 Dec 19.

Authors

Djordje S Popovic¹, Dimitrios Patoulias², Luigi Gnudi³, Christos S Mantzoros⁴

Affiliations

¹ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
² Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital Hippokration, Thessaloniki, Greece.
³ School of Cardiovascular and Metabolic Medicine & Science, Kings College London, Department of Diabetes and Endocrinology, Guy's and St Thomas Hospital NHS Foundation Trust, London, UK.
⁴ Beth Israel Deaconess Medical Center and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA. Electronic address: cmantzor@bidmc.harvard.edu.

PMID: 38122894
DOI: 10.1016/j.metabol.2023.155763

No abstract available

Keywords: Diabetic kidney disease; Finerenone; Glucagon-like peptide-1 receptor agonists; Sodium-glucose co-transporter 2 inhibitors; Type 1 diabetes.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 1* / complications
Diabetes Mellitus, Type 2* / complications
Diabetic Nephropathies* / etiology
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucagon-Like Peptide-1 Receptor